Avutometinib, Defactinib, and Everolimus for the Treatment of RAS Pathway Mutant Endometrial Cancer

Inclusion Criteria

• Participants must have histologically or cytologically confirmed recurrent RAS mutant endometrial cancer. RAS pathway gene activating mutations include KRAS, NRAS, HRAS, BRAF, MEK1, and MEK2 activating mutations. Any endometrial histology is permitted, including endometrioid, clear cell, mesonephric, and serous
• Participants must have received prior immune checkpoint inhibition treatment alone or in combination
• Unlimited prior systemic therapies are permitted, including any number of prior MEK inhibitor regimens
• Ability to understand and willingness to sign a written informed consent document
• Willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• The effects of avutometinib and defactinib on the developing human fetus are unknown. For this reason, women of child-bearing potential must have a negative urine or serum pregnancy test within 72 hours of starting study and agree to use adequate contraception prior to study entry, for the duration of study participation, and for 3 months after the last dose of study drug. This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following: * Postmenopausal (no menses in greater than or equal to 12 consecutive months) * History of hysterectomy or bilateral salpingo-oophorectomy * Ovarian failure (follicle stimulating hormone and estradiol in menopausal range, who have received whole pelvic radiation therapy) * History of bilateral tubal ligation or another surgical sterilization procedure * The use of hormonal contraception methods is not recommended for this study. Approved methods of birth control are as follows: Tubal ligation or hysterectomy, subject/partner post vasectomy, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
• Participants must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
• Age ≥ 18 years
• Absolute neutrophil count ≥ 1,000/mcL
• Platelets ≥ 100,000/mcL
• Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
• Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x institutional ULN
• Creatinine clearance ≥ 50 ml/min
• Hemoglobin ≥ 9 g/dL * If a red blood cell transfusion or erythropoiesis‑stimulating agent has been administered the hemoglobin must remain stable and ≥ 9 g/dL for at least 1 week prior to first dose of study intervention
• Creatine phosphokinase (CPK) ≤ 2.5 x ULN
• Adequate cardiac function with left ventricular ejection fraction ≥ 50% by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan
• Corrected QT (QTc) interval ≤ 460 ms using Fredericia’s QT correction formula (at baseline from electrocardiograms [ECGs]). NOTE: Patients with a right or left bundle branch block are allowed to have a QTc > 460ms
• Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class I or II and stage A or B
• For dose expansion cohort: the patient must be willing to undergo biopsy procedure at screening and on treatment

Exclusion Criteria

• Participants who are pregnant or lactating
• Participants with sarcoma components of their endometrial cancer, except carcinosarcoma
• Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks prior to cycle 1 day 1
• Participation in an interventional anti-cancer study (clinical trial) within 3 weeks prior to cycle 1 day 1
• Major surgery within four weeks before cycle 1 day 1
• A history of congestive heart failure (CHF) of New York Heart Association (NYHA) class ≥ 3, or history of myocardial infarction (MI) within 3 months
• Participants with a history of severe obstructive pulmonary disease, pulmonary hypertension, and/or pulmonary fibrosis in the opinion of treating medical doctor (MD)
• History of medically significant rhabdomyolysis in the opinion of treating MD
• For participants with prior MEK inhibitors, any history of or ongoing grade 4 toxicity deemed related to MEK inhibitor
• Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose; participants with controlled infection in the opinion of treating MD or on prophylactic antibiotics are permitted in the study
• Active hepatitis B, or C infection as indicated by detectable viral load. Known HIV seropositivity with detectable viral load. Participants with an undetectable viral load are eligible for the trial
• Any underlying condition that would significantly interfere with the absorption of an oral medication or inability to take oral medications in the opinion of treating MD
• Patients with psychiatric illness/social situations that would limit compliance with study requirements
• Participants with symptomatic brain lesions
• Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation). Subjects with known deep vein thrombosis/pulmonary embolism that are under appropriate anti-coagulation treatment are eligible
• History of clinically significant hemoptysis within 1 month prior to study enrollment for any tumor type
• Current, non-healing wound, ulcer or bone fractures
• Known hypersensitivity to defactinib, avutometinib, everolimus, and/or other rapamycin derivatives
• Current warfarin use. Patients who are being treated with warfarin within 7-14 days prior to enrollment for deep vein thrombosis/pulmonary embolism may be eligible if their warfarin therapy can be converted to low molecular weight heparin or direct oral anticoagulants (DOACs). Patients who can be transitioned should have international normalized ratio (INR) checked after 5 days on low molecular weight heparin or a direct oral anticoagulant (DOAC). Patients are eligible if the INR is ≤ 1.5 prior to the first study dose
• Current use of medications (with or without prescriptions), supplements, herbal remedies, or foods (grapefruit and grapefruit juice, Seville oranges and star fruit) with potential for drug-drug interactions with avutometinib and/or defactinib within 5 half-lives (if known), or if not known then 14 days prior to the first dose of study intervention, including: * Strong cytochrome P50 (CYP)3A4 inhibitors or inducers * Strong CYP2C9 inhibitors or inducers * Strong P-glycoprotein (P-gp) inhibitors or inducers * Strong breast cancer resistance protein (BCRP) inhibitors or inducers
• Specific concurrent ocular disorders: * History of glaucoma, history of retinal vein occlusion (RVO), predisposing factors for RVO, including uncontrolled hypertension, uncontrolled diabetes * History of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, intraocular pressure > 21 mmHg as measured by tonometry, or other significant ocular pathology, such as anatomical abnormalities that increase the risk for RVO * Active or chronic, visually significant corneal disorders, other active ocular conditions requiring ongoing therapy, or clinically significant corneal disease that prevents adequate monitoring of drug‑induced keratopathy. Examples of visually significant corneal disorders include corneal degeneration, active or recurrent keratitis, and other forms of serious ocular surface inflammatory conditions. Visually significant corneal disorders do NOT include dry eyes, blepharitis, and uncomplicated corneal erosions
• Severe skin disorder in the opinion of treating MD that has required systemic therapy within one year of the first dose of study intervention